Showing 1 - 6 results of 6 for search 'Nigel S. Key', query time: 0.02s Refine Results
  1. 1
    Prolonged Remission of Cancer of Unknown Primary following Initiation of Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria

    Prolonged Remission of Cancer of Unknown Primary following Initiation of Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria by Ming Y. Lim, Keith E. Volmar, Nigel S. Key

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Erratum to “Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome” [Kidney International Reports Volume 9, Issue 10, October 2024, Pages 3053-3056]

    Erratum to “Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome” [Kidney International Reports Volume 9, Issue 10, October 2024, Pages 3053-3056] by David Massicotte-Azarniouch, Daniel J. Crona, Priscilla Karnabi, Bhadran Bose, Patrick H. Nachman, Marc Carrier, Mark Canney, David W. Johnson, Taewoo Lee, Raja Ramachandran, Vivekanand Jha, Nigel S. Key, Vimal K. Derebail

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model

    Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model by Fatima Trebak, Mohammad O. Sako, Steven P. Grover, Karnsasin Seanoon, Izabela Pawlinski, Chatphatai Moonla, Michael W. Henderson, Vimal K. Derebail, Dougald M. Monroe, Patrick Ellsworth, Rafal Pawlinski, Malgorzata Kasztan, Nigel S. Key

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome

    Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome by David Massicotte Azarniouch, Daniel J. Crona, Priscilla Karnabi, Bhadran Bose, Patrick H. Nachman, Marc Carrier, Mark Canney, David W. Johnson, Taewoo Lee, Raja Ramachandran, Vivekanand Jha, Nigel S. Key, Vimal K. Derebail

    Published 2024-10-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years

    Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years by Annette von Drygalski, Esteban Gomez, Adam Giermasz, Giancarlo Castaman, Nigel S. Key, Susan U. Lattimore, Frank W. G. Leebeek, Wolfgang A. Miesbach, Michael Recht, Paul E. Monahan, Sandra Le Quellec, Steven W. Pipe

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial

    Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial by Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington, Doris V. Quon, Adam Giermasz, Maria Fernanda López Fernández, Gili Kenet, Gillian Lowe, Nigel S. Key, Carolyn M. Millar, Steven W. Pipe, Bella Madan, Sheng-Chieh Chou, Robert Klamroth, Jane Mason, Hervé Chambost, Flora Peyvandi, Elaine Majerus, Dominic Pepperell, Christine Rivat, Hua Yu, Tara M. Robinson, Margareth C. Ozelo

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: